Comparative Pharmacology
Head-to-head clinical analysis: FLUDROCORTISONE ACETATE versus KERLEDEX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLUDROCORTISONE ACETATE versus KERLEDEX.
FLUDROCORTISONE ACETATE vs KERLEDEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Mineralocorticoid receptor agonist; promotes sodium reabsorption and potassium excretion in renal distal tubules, increasing extracellular fluid volume. Also has glucocorticoid activity.
Kerledex is a selective serotonin reuptake inhibitor (SSRI) that potentiates serotonergic activity in the CNS by inhibiting the reuptake of serotonin at the presynaptic neuronal membrane.
0.1 mg orally once daily, range 0.05-0.2 mg/day
Intravenous: 500 mg every 6 hours; Oral: 250 mg every 8 hours.
None Documented
None Documented
Terminal elimination half-life is 3.5 hours (range 2–5 h); clinical effect duration exceeds half-life due to mineralocorticoid receptor binding.
Terminal half-life 12 hours (range 10–14) in normal renal function; extended to 30–50 hours in severe renal impairment (CrCl <30 mL/min); 6–8 hours in hepatic cirrhosis.
Renal (80%) as inactive metabolites; less than 5% unchanged; minor biliary/fecal elimination.
Renal: 70% unchanged; fecal/biliary: 20% as metabolites; 10% as minor metabolites. Total renal clearance 180 mL/min, active tubular secretion accounts for 60% of renal elimination.
Category D/X
Category C
Corticosteroid
Corticosteroid/Antibiotic Combination